Enhancing the Risk Stratification of Severe Arboviral diseases using host-response Biomarkers in Brazil.
- Funded by European Commission
- Total publications:0 publications
Grant number: 101206872
Grant search
Key facts
Disease
Unspecified, Unspecified…Start & end year
20252028Known Financial Commitments (USD)
$360,194.5Funder
European CommissionPrincipal Investigator
N/A
Research Location
BrazilLead Research Institution
FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONAResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Prognostic factors for disease severity
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
Arboviruses such as dengue, Zika, and chikungunya, are experiencing a rapid surge in incidence and geographical distribution, representing a global public health threat. Improved risk assessment tools for arboviral diseases are urgently needed to enhance clinical management, since current risk stratification is based on algorithms with limited prognostic accuracy. Strong evidence suggests that immune and endothelial activation markers can reliably identify infections likely to progress to severe outcomes; however, data on specific arboviruses are scarce and conflicting. The main aim of RISE-ARBB is to enhance early identification of severe arboviral diseases. The specific objectives are to: (1) evaluate head-to-head a wide panel of host-response biomarkers for early identification of severe arboviral diseases, using a large prospective cohort study and Luminex platform; (2) assess the prognostic performance of two novel point-of-care rapid triaging tests based on the quantification of sTREM1 and Angpt2 markers; (3) develop an evidence-based algorithm integrating the best performing marker(s) with clinical severity indicators to improve clinical guidelines; and (4) develop an exploitation strategy, including regulatory and go-to-market plan. Such objectives will be addressed through a prospective cohort study involving ~2,000 individuals over 1 year-old presenting with symptomatic arbovirus infection at emergency departments of 3 hospitals in Brazil, the global epicenter of arbovirus epidemics. The results have the ground-breaking potential to avoid preventable deaths and decrease health system costs during future arbovirus outbreaks and epidemics globally. This fellowship will enable me to upgrade my training in translational research on arboviral diseases in endemic settings and prognostic strategies for their management, while establishing a global network and laying the foundation for a successful ERC application and independent academic career.